<DOC>
	<DOCNO>NCT01843062</DOCNO>
	<brief_summary>The study design evaluate clinical efficacy , safety tolerability selumetinib radioactive iodine therapy patient differentiate thyroid cancer .</brief_summary>
	<brief_title>Study Comparing Complete Remission After Treatment With Selumetinib/Placebo Patient With Differentiated Thyroid Cancer</brief_title>
	<detailed_description>A Randomised , Double Blind Study Compare Complete Remission Rate Following 5-Week Course Selumetinib Placebo Single Dose Adjuvant Radioactive Iodine Therapy Patients Differentiated Thyroid Cancer .</detailed_description>
	<mesh_term>Thyroid Diseases</mesh_term>
	<mesh_term>Thyroid Neoplasms</mesh_term>
	<mesh_term>Iodine</mesh_term>
	<mesh_term>Cadexomer iodine</mesh_term>
	<criteria>Differentiated thyroid cancer Tumor &gt; 4 cm , Gross extrathyroid extension , 1 lymph node &gt; 1 cm , 5 lymph node size Previous thyroidectomy Must able receive radioactive iodine therapy Must able receive Thyroid Stimulating Hormone suppression Exclusion criterion : Metastaic disease Anaplastic thyroid cancer , medullary thyroid cancer Hurthle cell carcinoma Presence antiTg antibody Previous treatment radiation Unresolved toxicity â‰¥ common terminology criterion adverse event Grade 2</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>130 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Selumetinib , Differentiated Thyroid Cancer , AZD6244</keyword>
</DOC>